B

Biohit Oyj
OMXH:BIOBV

Watchlist Manager
Biohit Oyj
OMXH:BIOBV
Watchlist
Price: 2.4 EUR 2.13%
Market Cap: 36.3m EUR
Have any thoughts about
Biohit Oyj?
Write Note

Intrinsic Value

The intrinsic value of one BIOBV stock under the Base Case scenario is 3.32 EUR. Compared to the current market price of 2.4 EUR, Biohit Oyj is Undervalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BIOBV Intrinsic Value
3.32 EUR
Undervaluation 28%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation Backtest
Biohit Oyj

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BIOBV cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BIOBV?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Biohit Oyj

Provide an overview of the primary business activities
of Biohit Oyj.

What unique competitive advantages
does Biohit Oyj hold over its rivals?

What risks and challenges
does Biohit Oyj face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biohit Oyj.

Provide P/S
for Biohit Oyj.

Provide P/E
for Biohit Oyj.

Provide P/OCF
for Biohit Oyj.

Provide P/FCFE
for Biohit Oyj.

Provide P/B
for Biohit Oyj.

Provide EV/S
for Biohit Oyj.

Provide EV/GP
for Biohit Oyj.

Provide EV/EBITDA
for Biohit Oyj.

Provide EV/EBIT
for Biohit Oyj.

Provide EV/OCF
for Biohit Oyj.

Provide EV/FCFF
for Biohit Oyj.

Provide EV/IC
for Biohit Oyj.

Show me price targets
for Biohit Oyj made by professional analysts.

What are the Revenue projections
for Biohit Oyj?

How accurate were the past Revenue estimates
for Biohit Oyj?

What are the Net Income projections
for Biohit Oyj?

How accurate were the past Net Income estimates
for Biohit Oyj?

What are the EPS projections
for Biohit Oyj?

How accurate were the past EPS estimates
for Biohit Oyj?

What are the EBIT projections
for Biohit Oyj?

How accurate were the past EBIT estimates
for Biohit Oyj?

Compare the revenue forecasts
for Biohit Oyj with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biohit Oyj and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biohit Oyj against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biohit Oyj compared to its peers.

Compare the P/E ratios
of Biohit Oyj against its peers.

Discuss the investment returns and shareholder value creation
comparing Biohit Oyj with its peers.

Analyze the financial leverage
of Biohit Oyj compared to its main competitors.

Show all profitability ratios
for Biohit Oyj.

Provide ROE
for Biohit Oyj.

Provide ROA
for Biohit Oyj.

Provide ROIC
for Biohit Oyj.

Provide ROCE
for Biohit Oyj.

Provide Gross Margin
for Biohit Oyj.

Provide Operating Margin
for Biohit Oyj.

Provide Net Margin
for Biohit Oyj.

Provide FCF Margin
for Biohit Oyj.

Show all solvency ratios
for Biohit Oyj.

Provide D/E Ratio
for Biohit Oyj.

Provide D/A Ratio
for Biohit Oyj.

Provide Interest Coverage Ratio
for Biohit Oyj.

Provide Altman Z-Score Ratio
for Biohit Oyj.

Provide Quick Ratio
for Biohit Oyj.

Provide Current Ratio
for Biohit Oyj.

Provide Cash Ratio
for Biohit Oyj.

What is the historical Revenue growth
over the last 5 years for Biohit Oyj?

What is the historical Net Income growth
over the last 5 years for Biohit Oyj?

What is the current Free Cash Flow
of Biohit Oyj?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biohit Oyj.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biohit Oyj

Current Assets 12.9m
Cash & Short-Term Investments 5m
Receivables 6.9m
Other Current Assets 1m
Non-Current Assets 1.3m
Long-Term Investments 100k
PP&E 800k
Intangibles 400k
Current Liabilities 3m
Accounts Payable 800k
Other Current Liabilities 2.2m
Non-Current Liabilities 400k
Long-Term Debt 400k
Efficiency

Earnings Waterfall
Biohit Oyj

Revenue
14m EUR
Cost of Revenue
-5.4m EUR
Gross Profit
8.6m EUR
Operating Expenses
-6.9m EUR
Operating Income
1.6m EUR
Other Expenses
26k EUR
Net Income
1.7m EUR

Free Cash Flow Analysis
Biohit Oyj

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BIOBV Profitability Score
Profitability Due Diligence

Biohit Oyj's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
ROIC is Increasing
Positive 3-Years Revenue Growth
56/100
Profitability
Score

Biohit Oyj's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

BIOBV Solvency Score
Solvency Due Diligence

Biohit Oyj's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Biohit Oyj's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BIOBV Price Targets Summary
Biohit Oyj

Wall Street analysts forecast BIOBV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BIOBV is 2.75 EUR with a low forecast of 2.73 EUR and a high forecast of 2.84 EUR.

Lowest
Price Target
2.73 EUR
14% Upside
Average
Price Target
2.75 EUR
15% Upside
Highest
Price Target
2.84 EUR
18% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BIOBV?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BIOBV is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Biohit Oyj

Country

Finland

Industry

Health Care

Market Cap

36.4m EUR

Dividend Yield

0%

Description

Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. The company is headquartered in Helsinki, Etela-Suomen. The firm operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. The company provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company’s products are used in hospitals, healthcare centers and research institutions. The company operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.

Contact

ETELA-SUOMEN
Helsinki
Laippatie 1
+3589773861
www.biohithealthcare.com

IPO

1999-06-18

Employees

-

Officers

Founder, Deputy CEO, Member of Scientific Advisory Board & Director
Prof. Osmo Antero Suovaniemi M.D., Ph.D.
President & CEO
Mr. Jussi Hahtela
Chief Financial Officer
Mr. Jussi Sorvo
Head of Global Sales & Marketing
Graham Johnson B.Sc., BSc
Head of Diagnostics Department - Biohit Russia
Mr. Yulia Kubacheva
Chief Commercial Officer
Mr. Ilari Patrakka Msc (Econ.)
Show More
R&D Director
Mr. Panu Hendolin Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one BIOBV stock?

The intrinsic value of one BIOBV stock under the Base Case scenario is 3.32 EUR.

Is BIOBV stock undervalued or overvalued?

Compared to the current market price of 2.4 EUR, Biohit Oyj is Undervalued by 28%.

Back to Top